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Summary
The only molecular defect reported for the X-linked immunodeficiency WiskottAldrich syndrome
(WAS) is the abnormal electrophoretic behavior of the major T lymphocyte sialoglycoprotein
CD43. Since the 70 to 80 O-linked carbohydrate chains of CD43 are known to influence markedly
its electrophoretic mobility, we analyzed the structure and the biosynthesis of O-glycans of CD43
in lymphocytes from patients with WAS. Immunofluorescence analysis with the carbohydrate
dependent anti-CD43 antibody T305 revealed that in 10 out ofthe 12 WAS patients tested increased
numbers ofT lymphocytes carry on CD43 an epitope which on normal lymphocytes is expressed
only after activation. Other activation antigens were absent from WAS lymphocytes. Western
blots of WAS cell lysates displayed a high molecular mass form of CD43 which reacted with
the T305 antibody and which could be found on in vivo activated lymphocytes but was absent
from normal unstimulated lymphocytes. To examine the O-glycan structures, carbohydrate labeled
CD43 was immunoprecipitated and the released oligosaccharides identified. WAS lymphocyte
CD43 was found to carry predominantly the branched structure NeuNAca2-3Gala1--"3
(NeuNAca2-3Ga101-4G1cNAc01-6) Ga1NAcOH whereas normal lymphocytes carry
the structure NeuNAca2-3Ga101--"3 (NeuNAca2--"6) Ga1NAcOH. Only after activation
NeuNAca2-3Gal01-"3 (NeuNAca2-3Gal01-4GlcNAc01-6) Ga1NAcOH becomes the
principal oligosaccharide on CD43 from normal lymphocytes. Analyzing the six glycosyltransferases
involved in the biosynthesis of these O-glycan structures it was found that in WAS lymphocytes
high levels of /31-6 N-acetyl-glucosaminyl transferase are responsible for the expression of
NeuNAca2-3Ga101--"3 (NeuNAca2-3Gal01-4GlcNAc01-6) Ga1NAcOH on CD43. The
gene responsible for WAS has not yet been identified but the results presented in this study
suggest that the primary defect in WAS may affect a gene which is involved in the regulation
of O-glycosylation.
T
he X-linked, recessive immunodeficiency, WiskottAldrich
syndrome (WAS),' is characterized by thrombocyto-
penia with reduced platelet volume and impaired aggrega-
tion, immunological defects affecting both humoral and cel-
lular responses, and eczema (1). The T lymphocytes in WAS
show an abnormal morphology (2), a reduced response in
the mixed lymphocyte reaction (3), and a progressive deple-
tion of the T lymphocyte dependent areas ofspleen and lymph
nodes leading to lymphopenia (4) . The only molecular de-
fect described so far in WAS is the lack or decreased expres-
sion ofthe major sialoglycoprotein ofhuman T lymphocytes
(= CD43, GP115, leukosialin, sialophorin) (5, 6) and the
'Abbreviations used in this paper: Ga1NAc, N-acetyl-D-galactosamine;
NeuNAc, N-acetyl neuraminic acid; WAS, Wiskott-Aldrich syndrome.
presence in three out ofeight patients ofa novel surface mol-
ecule of Mr 135 kD not found on normal lymphocytes (6).
However, the cDNA coding for CD43 has been cloned and
the gene has been localized on chromosome 16 (7, 8) which
excludes the possibility that a structural defect in the CD43
gene may be responsible for the reduced levels of the GP115
glycoprotein in WAS patients. Using an anti CD43 antibody
and Western blot analysis of T lymphocytes from a number
of WAS patients, a recent study showed that, although the
amount of CD43 may be reduced on WAS lymphocytes, bands
reacting with the specific antibody could be detected at higher
(135 kD) and lower (95 kD) apparent molecular mass than
that found on normal resting T lymphocytes (9). Since the
gene coding for CD43 has been shown to lack an intron within
the coding sequence (10, 11), these observations suggest that
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expression of CD43 in WAS T lymphocytes.
CD43 is aheavily glycosylated integral membrane protein
with 70-80O-linked carbohydrate chains (6, 12-14) . The struc-
ture of the O-glycans varies among different cell types (15)
and changes during T lymphocyte activation (16) . The car-
bohydrate structures have been shown to strongly influence
the migration of this glycoprotein in SDS-PAGE indicating
that in WAS T lymphocytes a change of the carbohydrate
chains couldbe responsible for the aberrant behavior ofCD43
on SDS-PAGE .
In the present study we undertook the analysis and char-
acterization of the carbohydrate structures ofCD43 from the
PBL of patients with WAS andcompared the structures and
the biosynthesis of the glycanswith those obtained from CD43
of normal resting and activated lymphocytes.
Materials and Methods
Materials .
￿
The rabbit anti-CD43 antiserum and themAbT305
(mouse IgGI) were generous gifts of Drs . S. Carlsson (Umei,
Sweden) andR.I . Fox (La Jolla, CA), respectively. The unlabeled
and FITC- or PE-labeled anti-CD3, anti-CD25, and anti-CD71
antibodies were obtained from Ortho Diagnostics (Raritan, NJ)
andfrom Becton Dickinson andCo . (Mountain View, CA). Unla-
beled IOB8 (mouse IgG1, anti-CD23) wasfrom Immunotech (Mar-
seilles, France) . Human recombinant IIr2 was from Janssen Bio-
chemicals (Beerse, Belgium) . PHAwas from Wellcome (Dartford,
England) . Tritiated sodium borohydride, UDP-[14C] N-acetyl-D-
galactosamine (GaINAc), UDP-[14C]Gal, UDP-["C]G1cNAc,
CMR[14C] N-acetyl neuraminic acid (NeuNAc), and [methyl- 1'C]
molwt standards were fromNew England Nuclear (Boston, MA);
GaINAc, G1cNAc, Gal01-3Ga1NAca1--"O-Benzyl, bovine sub-
maxillary mucin, asialo-bovine submaxillary mucin, andneuramin-
idase from Clostridium perfringens (type V) were purchased from
Sigma Chemical Co . (St . Louis, MO); fixed Staphylococcus aureus
(Pansorbin), neuraminidase from Vibrio cholerae and pronasewere
obtained from Calbiochem-Behring (La Jolla, CA) . Sephadex G-50
was purchasedfrom Pharmacia (Uppsala, Sweden), Bio-GelR4 from
Bio-Rad Labs (Richmond, CA), Sep-Pak C-18 disposable reversed
phase columns as well as a 5 /A C-18 reversed phaseHPLC column
(4.6 x 250mm)were from Waters Chromatography Division (Mil-
ford, MA) .
Preparation ofIkripheral Blood Lymphocytes.
￿
Bloodsamplesfrom
WASpatients or healthy volunteers were collected inEDTA (12.5
mM final concentration) and mononuclear cells were prepared by
centrifugation over a Ficoll-Hypaque (Pharmacia) gradient . For the
biochemical analysis monocytes were removedbyadherence to plastic
dishes inRPM11640 with 10% FCS(Gibco/BRL, Grand Island,
NY). Themonocytedepleted preparations usually containedmore
than 95% viable cells andbetween80 and85%CD3positive cells .
T lymphocytes were activated by incubation of PBMCs with 5
Rg/ml PHA or 50 ng/mlanti-CD3 (OKT3; Ortho Diagnostics)
in RPMI 1640 supplemented with 10% FCS and 25 U/ml 11,2
for 5 or 6 d with one change of medium on day 3.
Immunofluorescence Analysis.
￿
For the fluorescence analysis 5 x
105 PBMC were incubated for 30min on ice with the appropriate
amountsofantibody as indicated by the suppliers in a total volume
of 25 141 of PBS containing 2% BSA and 0.02% sodium azide .
The isotype matched control antibody and T305 were unlabeled
andwere revealed by an affinity-purified, PE-labeled goat anti-mouse
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antibody (Nordic, Tilburg, The Netherlands) . After three washes
with PBS/BSA the cells were labeled for 30 min at 0°Cwith FITC-
labeled anti-CD3 (Leu4) . In parallel experiments all antibodies were
also tested as single labels andcompared with the double labeling .
In both single and double labeling experiments the percentage of
cells reacting with onegiven antibody was always found to be iden-
tical . Immunofluorescence analysis was carried out on a FACS®
Star Plus (Becton-Dickinson and Co., Mountain View, CA)
cytofluorimeter set up for double fluorescence analysis. Side and
forward angle light scatterwas used to exclude dead cells and mono-
cytes identified in separate single labeling experiments by staining
with propidium iodide and OKM3, respectively. The cells were
gated on theCD3 positive population andthe fluorescence histo-
grams of the second fluorescence are presented with the relative
number ofcellson a linear scale plotted vs. the relative fluorescence
intensity on a logarithmic scale, both in arbitrary units .
SDS-Polyacrylamide GelElectrophoresis.
￿
Cells were lysed at 4°C
in 10 mM sodium phosphate, pH 7.4, 150mM NaCl, 1mM EDTA,
2mM PMSF, and0.5% NP-40and centrifuged for 15 min at 15,000
g. The lysates (25-100 P,g protein [17]) were subjected to SDS-
PAGE (18) on 7% polyacrylamide gels and the separated proteins
transferred to nitrocellulose membranes (Schleicher&Schull, Mainz,
W . Germany) (19) . CD43 was revealed either with the rabbit an-
tiserum or with T305 followed by affinity-purified second antibodies
coupled to alkaline phosphatase (Cappel, Cochranville, PA) . The
bound antibody-enzyme complexes were visualized with bromo-
chloroindoyl-phosphate and nitroblue-tetrazolium (Sigma Chem-
ical Co .) as described (20) . In some experiments theWestern blots
were incubated with [1151]-labeled protein G (New England Nu-
clear) followed by autoradiography. Immunoprecipitated samples
were subjected to SDS-PAGE and gels were treated for fluorography
with Enlightning (New England Nuclear) . [Methyl- 14C]methyl-
ated mol wt standards were myosin (200 kD), phosphorylase B
(97.4 kD), BSA(69 kD), ovalbumin (46 kD), and carbonic anhy-
drase (30 kD) .
Separation ofO-linked Oligosaccharides Isolatedfrom Leukosialin by
Gel Filtration on Bio-GelP-4 andHPLC. Cell surface carbohydrates
were labeled (21, 22) and CD43 analyzed as described (23) .
Glycopeptides were prepared from immunoprecipitated CD43 by
pronase digestion at 45°C for 72 h . After preincubation of pronase
(10 mg/ml) for 30 min at 37°C in 500 pl of 0.15 M Tris-HCI,
pH 8.1, 1 mM CaC11, three aliquots of 100 hg of pronase were
added at 20h intervals to each immunoprecipitate. Pronase-digested
material was fractionated by passage over a column (1.0 x 55.0
cm) of Sephadex G-50 (superfine) equilibrated with 0.1 M
NH 4HCO3, at a flow rate of 5 ml/h . The radioactive fractions
corresponding to the elution position ofglycopeptides were pooled,
concentrated and incubated in 50 mM NaOH, 1 M NaBH 4 for
16 h at 45°C. Thesampleswere then evaporated three timesunder
nitrogen, after addition of 1 volume of 100mM acetic acid in meth-
anol . /3-eliminated products were applied onto a Bio-GelR4 column
(1.0 x 110.0 cm) equilibrated in 0.1MNH 4HC03 . The flow rate
was 5 ml/h and each fraction contained 1 ml. An aliquot of each
fraction was used for scintillation counting . The oligosaccharides
separated by Bio-Gel P-4 were then analyzed by HPLC on a
Lichrosorb-NH1 column (Merck, Darmstadt, Germany) as de-
scribed previously (16) . A Varian HPLC apparatus (Model 5000 ;
Varian Associates, Inc., Palo Alto, CA)was used . Standard oligosac-
charides were obtained from human glycophorin (24) and from
CD43 of HIr60 cells (15) .
Glycosyltransferase Assays .
￿
Microsomes were prepared from 2-5
x 10 7 cells by suspending the cells in 15 mM Tris-HCI, pH 8.1,
containing 350mM sucrose, 5mM EDTA and 2mM PMSF andpassing them repeatedly through a 23-gauge needle. Incompletely
disrupted cells and nuclei were removed by centrifugation at 5,000 g
for 10 min and the microsomes were pelleted at 100,000 g. The
membranes were suspended in the homogenization buffer at a pro-
tein concentration of 10 mg/ml and stored at -20 °C until used.
a-N-acetyl-galactosaminyl transferase, /31-->3 and 01- ;4 galactosyl
transferases and a2-Y3 and a2-6 sialyl transferases were assayed
as described (25-29). The 01-6 N-acetyl-glucosaminyl transferase
assays followed the published procedures with minormodifications
(30). The incubation mixture contained in a total volume of 25
p,l 100 mM MES, pH 6.5, 10 mM MnC12, 0.05% Triton X-100,
100 mM G1cNAc, 2 mM ATP, 2.8 mM UDP-["C]G1cNAc
(20,000 cpm/nmol), 2 mM Ga101-3Ga1NAca1--"O-Benzyl and
50, 100, or 150 ug microsome protein. After incubation for 30
min or 120 min at 37°C the reaction was stopped by the addition
of water and the mixture passed over a column of Dowex 1 x
8 (Cl -). The flow through fraction was collected, diluted with
an equal volume of 100 mM NH4HCO3, and applied to a Sep-
Pak C-18 column. The column was washed with 100 mM
NH4HCO3 followed by water and the bound benzylated oligosac-
charides were eluted with 1.5 ml methanol and either counted
directly in a liquid scintillation counter or the methanol was evapo-
rated, the sample taken up in 100 Pl of water containing 0.1%
trifluoro-acetic acid and applied to a C-18 reversed phase HPLC
column. The column was eluted at 1 ml/min with a mixture of
83% acetonitrile and 17% water and the fractions taken at 1-min
intervals were counted for radioactivity.
Results
Immunofluorescence Analysis of Peripheral Blood Lympho-
cytes. The patients analyzed in this study were diagnosed
as having WAS by their severe thrombocytopenia associated
with a reduced platelet volume, eczema, and immuno-
deficiency. Some patients had been splenectomized at the time
of the analysis (Table 1) and some patients showed signs of
autoimmunity. In the flowcytometric analysis the amount
of T305 positive T lymphocytes was measured for patients
and control samples. The T305 antibody recognizes a carbo-
hydrate dependent epitope on CD43 expressed on activated
but not on resting human T lymphocytes (31). In normal
individuals only between 5 and 15% of the CD3 positive
PBLs carry the T305 epitope whereas in 10 out of the 12
WAS patients tested the amount of T lymphocytes recog-
nized by T305 was increased to between 22 and 74% (Table
1). Since the T305 antibody recognizes activated normal lym-
phocytes and since most patients suffered from infections at
the time of analysis the presence of activation antigens was
examined on the lymphocytes from patients which showed
high levels of the T305 epitope. In all five patients tested nei-
ther the 11,2 receptor a chain (CD25) nor the transferrin
receptor (CD71) were expressed in higher amounts than on
normal resting T lymphocytes.
Unstimulated WAS lymphocytes (patient FB, Table 1), un-
stimulated normal lymphocytes, and in vitro activated normal
lymphocytes were analyzed with antibodies to CD3 and to
the IL-2 receptor a chain (CD25), the transferrin receptor
(CD71) and with T305 (Fig. 1). In the unstimulated normal
CD3' lymphocytes <10% of the cells reacted with the
T305 antibody whereas >40% of the unstimulated WAS
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Table 1.
￿
Flowcytometric Analysis of Lymphocytes from WAS
Patients and Normal Individuals
SE: Spleenectomy.
CD3+ lymphocytes were stained with the T305 antibody.
As expected, the T305 antibody bound to almost all of the
in vitro activated normal T lymphocytes incubated for 5 d
with PHA and IL2. Although the unstimulated WAS T
lymphocytes reacted with the T305 antibody, they were nega-
tive for the receptors for IL2 and transferrin (Fig. 1, H and
K) as well as for other activation antigens such as 4F2 and
HLA-DR (not shown).
Western Blot Analysis of CD43 from WAS Lymphocytes.
PBLs from WAS patients were analyzed by immunoblotting
using a specific anti-CD43 antiserum. In all five patients (Figs.
2, A and C) the anti-CD43 antiserum revealed a band at 135
kD with variable intensity. Two patients (Fig. 2 A, lanes 3
and 5) revealed detectable bands only at 135 kD while two
other patients (Fig. 2 A, lanes 2 and 4) showed additional
bands of equal intensity at 100 kD and 80 kD, respectively.
The fifth patient (Fig. 2 C, lane 1) had bands at 135 kD and
at 120 M The PBLs of normal donors showed only a single
band at 120 kD which corresponds to the molecular mass
of CD43 in normal resting T lymphocytes (16). The pro-
teins which are stained at 200 kD and 70 kD are not related
to CD43 (12). To determine the molecular mass of CD43
on normal T lymphocytes activated in vivo, lymphocytes from
the synovial fluidof a patient with rheumatoid arthritis were
analyzed and revealed a broad CD43 band from 120 to 135
kD (Fig. 2 A, lane 6).
The murine mAb T305 has been shown to be specific for
the high mol wt form (135 kD) of CD43 found in activated
Patient
Age
(yr) SE" CD3'
( q )
T305'
( _ 0 5' Of
CD3+ cells)
CD25'
( 7 . Of
CD3' cells)
FB 4 + 65 40 1 .5
TC 2 + 57 33 1 .2
FD 9 - 65 47 2.0
RH 4 - 64 55 -
BL 2.5 + 62 53 -
FM 0.2 - 59 46 -
AO 4 - 54 60 -
NO 10 + 87 74 1 .0
AP 4 - 51 15 -
MSB 1 - 58 5 -
JS 3 + 71 22 -
AY 4 + 78 40 1 .0
Control
(N = 14) - 60-80 11 ± 6 <3NORMAL WAS NORMAL
RESTING RESTING ACTIVATED
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Figure 1.
￿
Immunofluorescence analysis ofWAS lymphocytes. Cells wereanalyzedby double immunofluorescence asdescribed in Materials and Methods.
The lymphocytes were gated for the CD3 positive cell population and the second fluorescence histograms are shown. Isotype matched control 10138
(A, B, C), T305 (D, E, 4 anti-CD25 (G, H, n, and anti-CD71 (J, K, L).Figure 2 .
￿
Western blots of total cell lysates ofWAS lymphocytes . (A) anti-CD43 antiserum ; Lane 1 : normal lymphocytes, lanes 2-5: WAS lympho-
cytes, lane 6: synovial fluid lymphocytes from a patient with rheumatoid arthritis panel . (B) T305 (clone G9), same samples as in (A) . (C)WAS lympho-
cytes, lane 1 : anti-CD43, lane 2: T305.
T-lymphocytes (12, 31) . As shown in Fig. 2, B and C, the
T305 antibody reacted with the 135 kD band of CD43 of
lymphocytes from WAS patients and of the synovial fluid
lymphocytes from the patient with rheumatoid arthritis. The
T305 antibody did not recognize the lower molecular mass
forms of CD43, i.e. the band at 120 kD .
Immunoprecipitation of CD43 Labeled in its Carbohydrate
Part . Normal and WAS PBLs were labeled in their carbo-
hydrate portions through the oxidation of sialic acid or after
removal of the sialic acid residues through the oxidation of
galactose followed by the reduction with tritiated sodium
borohydride. Immunoprecipitation of normal lymphocytes
with the rabbit anti-CD43 antiserum gave a labeled band at
120 kD while theWAS lymphocytes gave a band of 135 kD
(Fig . 3, lane 3) . After removal of the sialic acid residues the
apparent molecular mass of CD43 from the WAS patient
shifted to about 170kD (Fig. 3, lane 4) whereas normal asialo-
CD43 migrated at 150kD (Fig. 3, lane 2) . Following carbo-
hydrate labeling, immunoprecipitation ofCD43 from WAS
T lymphocytes revealed only one band from both native and
sialidase-treated lymphocytes indicating that the material of
lower molecular mass present on Western blots oflysates; from
some WAS patients (reference 9 and Fig. 2) is not present
in the patient tested or that these lower molecular mass forms
of CD43 do not contain sufficient amounts of carbohydrate
to be detectable.
Figure 3 .
￿
Immunoprecipitation ofCD43 from normal andWAS lym-
phocytes. The intactcells were labeled by periodate oxidation ofsialic acid
and reduction with [3H] sodium borohydride or, after removal of sialic
acid, by oxidation with galactose oxidase and reduction with 13H) sodium
borohydride according to the published procedures (21, 22) . CD43 was
immunoprecipitated with thecarbohydrate independent antiserum and ana-
lyzed on7% polyacrylamide gels . Lanes 1 and 2 show immunoprecipitates
from native and sialidase treated normal lymphocytes, and lanes 3 and 4
native and asialo CD43 from WAS lymphocytes.Carbohydrate Analysis ofCD43from WAS Lymphocytes.
￿
The
labeled oligosaccharides released from cell surface-labeled WAS
lymphocytes were analyzed by gel filtration on Bio-Gel P-4
and by HPLC on a Lichrosorb-NH2 column. Irrespective of
whether the labeling occurred through the sialic acid residues
ofafterremoval of the sialic acid through galactose or N-ace-
tylgalactosamine, the oligosaccharides released by alkaline boro-
hydride treatment from immunoprecipitated CD43 from WAS
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Figure 4.
￿
Carbohydrate analysis of WAS CD43. Lymphocytes were labeled in their cell surface carbohydrates, CD43 immunoprecipitated, the oligosac-
charides were released by alkaline/borohydride treatment and analyzed by gel filtration on Bio-Gel P-4 (A-C) and by HPLC on aminobonded silica
(Lichrosorb-NH2) (D-F). Oligosaccharide profiles from unstimulated normal (A and D) and WAS lymphocytes (B and E) and from normal lympho-
cytes cultured for 5 d in the presence of 50 ng/ml OKT3 and 50 U/ml IIr2 (C and F) are shown. (") Oligosaccharides from native and (0) from
neuraminidase treated cells. Fractions marked by the bars (®) in A-C were pooled and analyzed by HPLC (D-F). The numbered arrows indicate
the elution positions ofoligosaccharide standards: (1) NeuNAcca2-+3Gal/31-+3(NeuNActx2-3Galo1-4G1cNAco1-6)Ga1NAcOH ; (2) NeuNAcu2-
3Ga101-3(NeuNActx2-6)Ga1NAc0H ; (3) NeuNAcc12-"3Galol-3(Gal#1-4GIcNAcol-6)Ga1NAcOH and Ga1#1-3(NeuNAca2-3Gal01-
4G1cNAc131-6)GalNAc0H; (4) NeuNAcot2-3Galo1-3Ga1NAc0H and Gal,61-3(NeuNAco12-6)GalNAc0H ; (5) Ga1,B1-3(Gals1-4G1cNAc(31-"
6)Ga1NAcOH; (6) Gal01-3Ga1NAcOH; (7) Ga1NAcOH.
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lymphocytes displayed a different elution profile (Fig. 4) than
the oligosaccharides obtained from normal lymphocytes. The
major oligosaccharide from native or sialidase-treated WAS
CD43 eluted in gel filtration earlier than the predominant
oligosaccharide from normal CD43 indicating a higher mo-
lecular mass for the patient's oligosaccharide. In the HPLC
system the sugars released from CD43 of WAS lymphocytes
eluted later than those from normal lymphocytes indicatingagain a more complex structure for the carbohydrates derived
from WAS lymphocytes. In both analytical systems the elu-
tion profile of saccharides from WAS CD43 resembled closely
the pattern of those obtained from activated normal T lym-
phocytes.
The major structure released from native WAS CD43 co-
eluted from the gel filtrationas well as from the HPLC column
with the standard oligosaccharide NeuNAca2-3Galo1 -
3(NeuNAca2="3Galo1-4G1cNAco1-6)GalNAcOH. After
removal of the sialic acid residues and labeling in the galac-
tose moieties the major oligosaccharide from WAS CD43
eluted at the same position as Gala1-3(Galo1-4G1cNAco1
--"6)Ga1NAcOH in both gel filtration and HPLC. The rela-
tive amounts of labeled oligosaccharides released from CD43
from WAS as well as normal resting and activated lympho-
cytes are summarized in Table 2.
Biosynthesis of0-linked Carbohydrates in WAS Lymphocytes.
To studythebiosynthetic mechanisms underlyingthe change
of O-glycan structure in WAS T lymphocytes, microsomal
preparations ofnormal and WAS lymphocytes were analyzed
for the enzymatic activities of six glycosyltransferases. These
enzymes are known to be involved in the biosynthesis of
O-linked carbohydrate structures and specific assay protocols
have been published for each of the six transferases (25-30).
The enzymatic activities were calculatedfrom the radioactivity
transferred from [14C] -labeled sugar nucleotide donor sub-
strates to specific well defined acceptor substrates. The transfer
rateswere corrected for non-specific degradation and for the
transfer to endogenous substrates in the enzyme preparations
by subtracting the values obtained with control incubations
from which the acceptor substrates were omitted. The mean
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transfer rates of two protein concentrations are shown in Table
3. Five of the six enzymes displayed comparable activities
in resting normal and WAS lymphocytes. In contrast, the
/31-6G1cNAc transferase was only barely detectable (0.05
nmol/h mg protein) in normal lymphocytes whereas its ac-
tivity was comparable to that of other glycosyltransferases
(0.4 nmol/h mg protein) in WAS lymphocytes. The labeled
product of the /31-6 G1cNAc transferase reaction was charac-
terized by HPLC analysis on a reversed phase column. The
elution time of the product (22 min) corresponded to that
Table 3.
￿
Glycosyltransferase Activities
Lymphocytes
Enzymes
￿
Normal WAS
(nmol/h.mg
protein)
Glycosyltransferase activities were assayed in duplicates at two different
proteinconcentrations. Incubations were carried out at 37°C for30 min.
The acceptor substrates were as described in reference 16.
Table 2. Relative Amounts of Oligosaccharides Released from
Oligosaccharides
CD43
Resting
normal PBL
WAS
PBL
Activated
normal PBL
(%) (%) (%)
NeuNAcc12~3Galol~4G1cNAcgl
6
NeuNAcc12,3GalO1-3Ga1NAcOH 4.9 63 .0 48.0
NeuNAca2
1~h
6
NeuNAca2-, .3Ga1O1-3GalNAcOH 69.0 18.3 19.0
Galo1~4G1cNAco1 y
6
NeuNAccO~3Ga1o1-3Ga1NAcOH 7.5 10.6 20.0
NeuNAca2-3Ga1O1-4G1cNAcO1 " A
6
Galo1-3Ga1NAcOH
NeuNAca2
1% 6
GalO1-3Ga1NAcOH 18 .5 8.0 13.0
NeuNAca2-+3GalO1~3Ga1NAcOH
Polypeptide : ciGa1NAc transferase 0.33 0.2
Ga1NAc : X31-'3 Gal transferase 0.17 0.26
GalO1-3GalNAc : /31-6 G1cNAc transferase 0.05 0.4
G1cNAc : (31-+4 Gal transferase 2.38 1.49
Ga1NAc : o12-6 NeuNAc transferase 3.08 2.56
Ga1,Q1-3Ga1NAc : a2-3 NeuNAc transferase 0.17 0.2of the standard compound Gal#1-(G1cNAc#1-6)Ga1N-
Aca1-O-benzyl (32) which is the structure synthesized by
the 01-6GIcNAc transferase in the assay system used.
Discussion
The only molecular defect reported in the severe X-linked
immunodeficiency, WAS, is the abnormal expression ofCD43.
Recently the cDNA coding for CD43 has been cloned and
unambiguously localized on chromosome 16 (7, 8), indicating
that a structural defect of the protein is unlikely to be the
primary cause of the observed abnormalities of CD43 found
in WAS T lymphocytes. CD43 is the heavily glycosylated
major sialoglycoprotein ofhumanT lymphocytes. Most mAbs
developed against this glycoprotein recognize carbohydrate
dependent epitopes on the molecule (33). The mAb T305
is unique since it recognizes specifically a sialic acid depen-
dent epitope which is absent from normal resting T lym-
phocytes but is expressed on activated T lymphocytes (31,
34). The appearance of the T305 epitope on activated T lym-
phocytes and on several T cell lines coincides with the pres-
ence of a specific carbohydrate structure on the CD43 mole-
cule (15). The large amounts of sialylated O-linked glycans
on CD43 have a marked influence on its mobility in SDS-
PAGE and the glycan changes observed between resting and
activated normal T lymphocytes result in an increase in its
apparent mol wt from 120 kD in resting T lymphocytes to
135 kD in activated T lymphocytes (16). Among the differ-
ently glycosylated CD43 molecules the mAb T305 recog-
nizes only the high molecular mass form of CD43 and on
all cell types tested the reactivity of T305 is associated with
the presence ofthe structure NeuNAcc12-3Gal#1-3 (Neu-
NAca2-3Galo1-4G1cNAco1-6)Ga1NAca1-Ser/Thr on
human CD43 (15) .
The immunofluorescence analysis ofWAS lymphocytes re-
vealed, in 10 out of the 12 patients analyzed, an increased
percentage of T305 + T lymphocytes as compared to normal
T lymphocytes. Although the T305 epitope on CD43 can
be considered an activation antigen, the lymphocytes of the
WAS patients were negative with other activation markers
notably the receptors for IIr2 (CD25) and transferrin. The
amount of T305 positive T cells in WAS patients is highly
variable. However a majority of the patients studied showed
significantly higher than normal levels of T305 reactive T
cells. This heterogeneity of T305 levels is in agreement with
earlier reports on CD43 in WAS lymphocytes (5, 6, 9). In
addition, the Western blot analysis confirmed the previous
reports (6, 9) showing abnormally migrating CD43 mole-
cules in lymphocytes from WAS patients. Although most
patients examined in these studies showed low Mr forms of
CD43 a number of the patients exhibited also a band at 135
kD which was thought to be related to CD43. However,
in this study all lysates from the five WAS patients analyzed
showed one isoform ofCD43 at 135 kD whereas only a single
band of CD43 at 120 kD was revealed on blots from control
cells. In all samples, only the high molecular mass form of
CD43 reacted with the T305 antibody confirming the im-
munofluorescence data from WAS lymphocytes and demon-
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strating that the T305 antibody recognizes an epitope on the
CD43 molecule present on WAS T lymphocytes as well as
on activated normal T lymphocytes.
One patient was studied in greater detail; his lymphocytes
were isolated and the cell surface carbohydrates labeled, CD43
immunoprecipitated and the O-linked glycans isolated after
alkali/borohydrate cleavage. The carbohydrate independent
anti-CD43 antiserum immunoprecipitated only a single band
from WAS lymphocytes which migrated in SDS-PAGE at
135 kD. Normal lymphocytes gave also a single band with
a Mr of 120 kD. The difference in mobility between the im-
munoprecipitated CD43 molecules from WAS and normal
T lymphocytes was not due to different amounts of sialic
acid as had been suggested in a previous report (9) since
the treatment of the cells with sialidase and the labeling of
the underlying galactose residues did not abolish the differ-
ence in migration.
In the experiments described above the CD43 from WAS
lymphocytes behaved at least in part like the CD43 from ac-
tivated T cells of normal individuals indicating strongly that
carbohydrate changes may be responsible for the altered be-
havior of CD43 in WAS lymphocytes. The structural anal-
ysis of the 0-linked carbohydrates of CD43 confirmed this
hypothesis. The native or desialylated O-glycans released from
WAS CD43 eluted at the same positions as the oligosaccha-
ridesfrom CD43 from activated T lymphocytes and very little
material couldbe found which corresponded to the oligosac-
charides present on normal resting lymphocytes. From these
results and from the comparison with the chromatographic
behavior of well defined O-glycan standards it can be con-
cluded that CD43 of resting WAS T lymphocytes carries in-
creased amounts ofthe carbohydrate structure NeuNAcca2-
3Gal/31-3(NeuNAcci2-3Gal#1-4G1cNAca1-6)Ga1N-
Aca1-Ser/Thr which is found on normal T lymphocytes
only after they are activated.
In normal T cells the change from the simpler structure
NeuNAca2-GalO1-3(NeuNAca2-6)Ga1NAca1-Ser/
Thr on resting cells to the more complex saccharides
NeuNAca2-3Galo1-3(NeuNAca2-3Gal,fl1-4G1cN-
Aco1-6)Ga1NAcca1-Ser/Thr on activated cells is brought
about by the induced expression of a 01-6GIcNAc trans-
ferase and by the simultaneous decrease of the a2-6NeuNAc
transferase activity which competes with the X31-6G1cNAc
transferase for the same acceptor substrate Galo1-" 3Ga1N-
Aca1-Ser/Thr (16). The analysis of the glycosyltransferases
involved in the biosynthesis of O-glycans in WAS T cells re-
vealed that compared to normal resting T lymphocytes the
amount of01-6GIcNAc transferase was increased eight-fold.
However, the a2-6 sialyltransferase showed about the same
level ofactivity in WAS and normal lymphocytes. The results
suggest that in WAS patients the increase of 01-6GIcNAc
transferase alone is responsible for the change in the carbohy-
drate structures of CD43. A recent report describing the
glycosyltransferase activities in T lymphocytes from seven WAS
patients confirms that increased levels of01-6GIcNAc trans-
ferase activities are associated with the WAS. Interestingly,
in contrast to normal lymphocytes, WAS T cells appear to
loose the X31-"6 G1cNAc transferase activity during activa-tion (35) . This is in agreement with an earlier finding showing
that EBV transformed lymphocytes from two WAS patients
express lower levels of this enzyme than EBV transformed
normal B lymphocytes (36) .
The results described in this study present evidence that
the 0-linked carbohydrate structures on CD43 from WAS
lymphocytes are altered as compared to O-glycans from normal
resting T cells . The abnormal glycosylation of CD43 is the
only molecular alteration presently defined in WAS. How-
ever, in addition, CD43 from WAS lymphocytesmaybe more
rapidly degraded than normal CD43 since lower molecular
mass forms ofCD43 could be easily detected in WAS lym-
phocytes . Together these modifications could result in a com-
plete absence ofnormally glycosylatedCD43 on restingWAS
T lymphocytes . The precise role of CD43 or of its carbohy-
drate is not known but several recent reports (37-40) indi-
cate that CD43 may be involved in T cell activation .
The gene responsible for WAS has not yet been identified
but the results presented in this study suggest that the pri-
mary defect in WAS may affect a gene which is involved in
the regulation of O-glycosylation. The altered 0-linked car-
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